

**MUSIC11**

**Prostate Cancer: Follow-up Testing for Patients on Active Surveillance  
for at Least 30 Months**

|   |   |
|---|---|
| <b>Description</b>                            | Percentage of patients on active surveillance that have 2 or more tumor burden reassessments and 3 PSA tests in first 30 months since diagnosis |
| <b>Measure Type</b>                           | Process   |
| <b>High Priority Measure?</b>                 | No  |
| <b>Denominator</b>                            | Patients aged 30 or older with new diagnosis of low and low-intermediate prostate cancer (Gleason 6 or low volume Gleason 3+4)                  |
| <b>Numerator</b>                              | Patients on active surveillance that have 2 or more tumor burden reassessments and 3 PSA tests in first 30 months since diagnosis               |
| <b>Denominator Exclusions</b>                 | Prostate cancer patients under 30 years of age; Patients that have had prior treatment for prostate cancer                                      |
| <b>Denominator Exceptions</b>                 | None  |
| <b>Numerator Exclusions</b>                   | None  |
| <b>Risk-adjusted?</b>                         | No  |
| <b>Inverse Measure?</b>                       | No  |
| <b>Care Setting</b>                           | Ambulatory Care: Clinician Office/Clinic, Outpatient Services   |
| <b>Includes Telehealth?</b>                   | No  |
| <b>Proportional Measure?</b>                  | Yes   |
| <b>Continuous Variable Measure?</b>           | No  |
| <b>Ratio Measure?</b>                         | No  |
| <b>NQF Number</b>                             | N/A   |
| <b>National Quality Strategy (NQS) Domain</b> | Effective Clinical Care   |
| <b>Meaningful Measure Area</b>                | Appropriate Use of Healthcare   |